An interventional study of Single Bipolar Ablation and Double Parallel Bipolar Ablation in Low Back Pain and Chronic Low Back Pain (CLBP), sponsored by Axon srl. Not yet recruiting at 3 sites in Italy. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Axon srl · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Low Back Pain with a site in Italy — 12 open to participants now, 13 under way, 1 of them phase 3. Low Back Pain · Italy.
Among the 56 studies in Low Back Pain with a site in Italy, this one is the 20th largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2027, is one of 21 with no phase, reaches primary completion later than 12 of the 12 other live ones, and was the 56th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →12 of the 56 studies in Low Back Pain with a site in Italy are open now. Recruiting first, the newest first:
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18–90
Manusapiens · Sites in Italy
Ages 20–40 · Women only · Healthy volunteers
Fondazione Don Carlo Gnocchi Onlus · Sites in Italy
Ages 18+
International Institute of Behavioral Medicines · Sites in Italy
Ages 11–30
International Institute of Behavioral Medicines · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 25 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 5 · Phase 4 7
First in 2005; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 69 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 67 across the 40 interventional studies, 104 across the 15 observational. Of the 34 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 56 have an industry lead sponsor. The 10 most frequent:
Axon srl is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Axon srl has 1 study filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Low Back Pain with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07568353G. d'Annunzio UniversityBrain Connectivity and Perceptive Surfaces in Chronic Low Back Pain (SUPER-RMNf) | 2027-05-31 |
| NCT07647757Federico II UniversityNeurolyser XR for the Treatment of Sacroiliitis | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 56 studies in Low Back Pain with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether the Spinery® RF Generator and its sterile single-use accessories can safely lower disability and pain in adults with long-term low back pain that is thought to come from changes inside the vertebral bones of the lower spine. This type of pain is called vertebrogenic chronic low back pain.
The study will include adults whose low back pain has lasted for at least 6 months and has not improved enough with non-surgical care. Participants must also have specific changes on spine magnetic resonance imaging (MRI), called Modic type 1 changes or selected Modic type 2 changes, at one or more levels between L3 and S1.
The main questions this study aims to answer are:
All participants will receive treatment with the Spinery® RF Generator and accessories. There is no untreated comparison group. Participants will be assigned by chance to one of three ways of performing the radiofrequency ablation procedure. Radiofrequency ablation uses controlled heat to treat a small target area. In this study, the target is the basivertebral nerve, a nerve inside the vertebral body that may contribute to low back pain in some people.
Participants will:
BASILEA is a prospective, multicenter, single-arm clinical investigation of the investigational use of the Spinery® RF Generator and its sterile single-use accessories for basivertebral nerve ablation in adults with vertebrogenic chronic low back pain.
Vertebrogenic chronic low back pain is a type of low back pain believed to arise from the vertebral endplates and the vertebral body. In this study, eligible participants must have chronic isolated low back pain that has not responded adequately to at least 6 months of conservative treatment. Participants must also have MRI findings considered consistent with vertebrogenic pain at one or more vertebral levels from L3 to S1. These findings include Modic type 1 changes or Modic type 2 changes only when associated with edema-like signal changes on T2/STIR MRI sequences and considered clinically concordant with the participant's symptoms.
The Spinery® RF Generator is used together with its dedicated sterile single-use accessories, including the Spinery® Kit and the Spinery® Cooling Connection. The Spinery® RF Generator is a software-controlled radiofrequency generator designed to deliver controlled bipolar radiofrequency energy. The sterile single-use accessories allow percutaneous vertebral access, positioning of the radiofrequency probe, energy delivery, and probe cooling during the procedure.
The procedure is minimally invasive and percutaneous. During the procedure, the physician introduces one or more radiofrequency probes into the vertebral body under imaging guidance, such as fluoroscopy or computed tomography. The generator then delivers controlled radiofrequency energy to the intended intraosseous target region. The investigational treatment is intended to ablate the basivertebral nerve within the vertebral body.
All participants will receive active treatment. The study does not include a concurrent untreated or sham control group. Participants will be randomized in a 1:1:1 ratio to one of three protocol-defined ablation modalities: single bipolar ablation, double parallel bipolar ablation, or double cross bipolar ablation. This internal randomization is intended to balance the use of the three technical approaches during the study. The main clinical analysis will evaluate the pooled study population rather than formally compare the three ablation modalities as separate treatment groups.
The primary clinical assessment is the change in Oswestry Disability Index score from baseline to 3 months. The Oswestry Disability Index is a questionnaire used to measure how much low back pain affects daily activities. A lower score after treatment indicates improvement in disability.
Safety and performance will also be evaluated. One key safety and performance assessment is the completion of the ablation procedure without device-related adverse events. Additional assessments include pain intensity using the Visual Analogue Scale, quality of life using the EQ-5D-5L questionnaire, technical success, targeting success, procedural success, and adverse events through 6 months of follow-up.
MRI will be performed at baseline and about 6 weeks after treatment. The baseline MRI is used to support participant selection and to document the relevant vertebral findings. The 6-week MRI is used to assess whether the ablation zone reached the intended basivertebral target region inside each treated vertebral body. This MRI assessment supports evaluation of targeting success and is separate from the main clinical effectiveness assessment at 3 months.
Clinical follow-up visits are planned at 3 months and 6 months after treatment. The 3-month visit is used for the primary clinical effectiveness assessment. The 6-month visit is used to evaluate whether any improvement in disability, pain, and quality of life is maintained over time and to continue safety follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any MRI or other imaging evidence of alternative or additional clinically relevant lumbar pathology that could explain the participant's pain or confound study outcomes, such as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive active treatment using the Spinery® RF Generator and its sterile single-use accessories with the single bipolar ablation modality. In this approach, one cooled bipolar radiofrequency probe is introduced percutaneously into the target vertebral body under imaging guidance, such as fluoroscopy and/or CT, according to the protocol-defined procedure. Radiofrequency energy is delivered by the Spinery® RF Generator through the dedicated sterile single-use accessories to treat the intended basivertebral nerve target region. The number of treated vertebral bodies is determined according to the protocol-defined affected level(s), from L3 to S1. Participants will undergo the same post-treatment assessments as the other study arms, including MRI at approximately 6 weeks and clinical follow-up at 3 and 6 months.
Device: Single Bipolar Ablation
Participants assigned to this arm will receive active treatment with the Spinery® RF Generator and its sterile single-use accessorie using the double parallel bipolar ablation modality. In this approach, two cooled bipolar radiofrequency probes are introduced percutaneously into the target vertebral body under imaging guidance, such as fluoroscopy and/or CT, and positioned according to the protocol-defined parallel configuration. Radiofrequency energy is delivered by the Spinery® RF Generator through the dedicated sterile single-use accessories to treat the intended basivertebral nerve target region. The number of treated vertebral bodies is determined according to the protocol-defined affected level(s), from L3 to S1. Participants will undergo the same post-treatment assessments as the other study arms, including MRI at approximately 6 weeks and clinical follow-up at 3 and 6 months.
Device: Double Parallel Bipolar Ablation
Participants assigned to this arm will receive active treatment with the Spinery® RF Generator and its sterile single-use accessorie using the double cross bipolar ablation modality. In this approach, two cooled bipolar radiofrequency probes are introduced percutaneously into the target vertebral body under imaging guidance, such as fluoroscopy and/or CT, and positioned according to the protocol-defined cross configuration. Radiofrequency energy is delivered by the Spinery® RF Generator through the dedicated sterile single-use accessories to treat the intended basivertebral nerve target region. The number of treated vertebral bodies is determined according to the protocol-defined affected level(s), from L3 to S1. Participants will undergo the same post-treatment assessments as the other study arms, including MRI at approximately 6 weeks and clinical follow-up at 3 and 6 months.
Device: Double Cross Bipolar Ablation
Single bipolar ablation is performed using the Spinery® RF Generator and its dedicated sterile single-use accessories, including the Spinery® Kit and the Spinery® Cooling Connection. In this modality, one cooled bipolar radiofrequency probe is introduced percutaneously into the target vertebral body under imaging guidance, such as fluoroscopy and/or CT. Controlled bipolar radiofrequency energy is delivered to the intended basivertebral nerve target region according to the protocol-defined parameters.
Also known as: Spinery® RF Generator, Spinery® Kit, Spinery® Cooling Connection
Double parallel bipolar ablation is performed using the Spinery® RF Generator and its dedicated sterile single-use accessories, including the Spinery® Kit and the Spinery® Cooling Connection. In this modality, two cooled bipolar radiofrequency probes are introduced percutaneously into the target vertebral body under imaging guidance, such as fluoroscopy and/or CT, and positioned according to the protocol-defined parallel configuration. Controlled bipolar radiofrequency energy is delivered to the intended basivertebral nerve target region.
Also known as: Spinery® RF Generator, Spinery® Kit, Spinery® Cooling Connection
Double cross bipolar ablation is performed using the Spinery® RF Generator and its dedicated sterile single-use accessories, including the Spinery® Kit and the Spinery® Cooling Connection. In this modality, two cooled bipolar radiofrequency probes are introduced percutaneously into the target vertebral body under imaging guidance, such as fluoroscopy and/or CT, and positioned according to the protocol-defined cross configuration. Controlled bipolar radiofrequency energy is delivered to the intended basivertebral nerve target region.
Also known as: Spinery® RF Generator, Spinery® Kit, Spinery® Cooling Connection
Mean Change in Oswestry Disability Index Score From Baseline to 3 Months
The Oswestry Disability Index is used to assess disability related to low back pain. The score ranges from 0 to 100, where 0 represents no disability and 100 represents maximum disability. Higher scores indicate worse disability. The change will be calculated as the Oswestry Disability Index score at 3 months minus the Oswestry Disability Index score at baseline. A negative change indicates improvement, while a positive change indicates worsening.
Time frame: Baseline and 3 months after treatment
Completion of the Ablation Procedure Without Device-Related Adverse Events
This outcome evaluates whether the ablation procedure is completed without adverse events related to the investigational device. Device-related adverse events will be assessed by the investigator according to the protocol.
Time frame: During the procedure and through completion of the post-procedure assessment on the day of treatment
Mean Change in Oswestry Disability Index Score From Baseline to 6 Months
The Oswestry Disability Index is used to assess disability related to low back pain. The score ranges from 0 to 100, where 0 represents no disability and 100 represents maximum disability. Higher scores indicate worse disability. The change will be calculated as the Oswestry Disability Index score at 6 months minus the Oswestry Disability Index score at baseline. A negative change indicates improvement, while a positive change indicates worsening.
Time frame: Baseline and 6 months after treatment
Mean Change in Visual Analogue Scale Pain Score From Baseline to 3 and 6 Months
The Visual Analogue Scale is used to assess low back pain intensity. The score ranges from 0 to 10, where 0 represents no pain and 10 represents the worst imaginable pain. Higher scores indicate worse pain. The change will be calculated as the Visual Analogue Scale score at each follow-up visit minus the Visual Analogue Scale score at baseline. A negative change indicates improvement, while a positive change indicates worsening.
Time frame: Baseline, 3 months, and 6 months after treatment
Mean Change in EQ-5D-5L Index Score From Baseline to 3 and 6 Months
The EuroQol 5-Dimension 5-Level index score is used to assess health-related quality of life. In this study, the index score will be calculated using the Italian EQ-5D-5L value set. Scores range from -0.571 to 1, where -0.571 represents the worst health state and 1 represents full health. Higher scores indicate better health-related quality of life. The change will be calculated at 3 months and 6 months compared with baseline. A positive change indicates improvement, while a negative change indicates worsening.
Time frame: Baseline, 3 months, and 6 months after treatment
Technical Success of the Ablation Procedure
Technical successTechnical success is defined as the ability to access the treatment site and complete the ablation procedure according to the protocol-defined procedure. is defined as the ability to access the treatment site and complete the ablation procedure according to the protocol-defined procedure.
Time frame: During the procedure
Targeting Success Confirmed by 6-Week MRI
Targeting success is defined as successful targeting of the intended basivertebral region, confirmed by magnetic resonance imaging performed approximately 6 weeks after treatment according to the protocol-defined imaging criteria.
Time frame: 6 weeks after treatment
Procedural Success
Procedural success is defined as successful completion of the procedure with achievement of both technical success and targeting success according to the protocol-defined criteria.
Time frame: During the procedure and 6 weeks after treatment
Plan to share: No — Individual participant data will not be shared. Aggregate study results may be reported in scientific publications, regulatory submissions, and public registry updates.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.
Of 56 industry-sponsored interventional studies with no phase under Low Back Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 12 months is below that.
Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Axon srl